Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders
First Claim
1. A method of treating an individual having Parkinson'"'"'s disease with a therapeutically effective amount of a pharmaceutical composition comprising a protease, a lipase, and an amylase, comprising:
- measuring a level of fecal chymotrypsin in a stool sample of the individual;
comparing the level of fecal chymotrypsin with a normal fecal chymotrypsin level; and
administering the pharmaceutical composition comprising a protease, a lipase, and an amylase to the individual if the level of fecal chymotrypsin in the individual is less than the normal fecal chymotrypsin level.
1 Assignment
0 Petitions
Accused Products
Abstract
A method for treating a Parkinson'"'"'s patient with digestive/pancreatic enzymes involves administering an effective amount of digestive/pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder. In addition, a method is provided for determining whether an individual has, or may develop, Parkinson'"'"'s disease or related dysautonomic disorders and for determining whether an individual will benefit from the administration of pancreatic/digestive enzymes to treat the dysautonomic disorder.
216 Citations
8 Claims
-
1. A method of treating an individual having Parkinson'"'"'s disease with a therapeutically effective amount of a pharmaceutical composition comprising a protease, a lipase, and an amylase, comprising:
-
measuring a level of fecal chymotrypsin in a stool sample of the individual; comparing the level of fecal chymotrypsin with a normal fecal chymotrypsin level; and administering the pharmaceutical composition comprising a protease, a lipase, and an amylase to the individual if the level of fecal chymotrypsin in the individual is less than the normal fecal chymotrypsin level. - View Dependent Claims (2, 3, 6, 7)
-
-
4. A method of treating an individual having Parkinson'"'"'s disease comprising:
administering a pharmaceutical composition comprising a protease, a lipase, and an amylase to the individual if the level of fecal chymotrypsin in the individual is less than a normal fecal chymotrypsin level, wherein the level of fecal chymotrypsin is measured in a stool sample of the individual. - View Dependent Claims (5, 8)
Specification